---
title: 'Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic
  Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World
  Cohort/GUARDIANS Project'
date: '2024-09-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39272856/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240914193229&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Combinations of immune-checkpoint inhibitors (ICIs) are
  the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC)
  patients. In this multicenter study, we evaluated the RW safety and efficacy of
  cabozantinib plus nivolumab in mRCC ...'
disable_comments: true
---
INTRODUCTION: Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC ...